The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-Type unresectable metachronous colorectal carcinoma with liver metastases

Journal of Cancer Research and Therapeutics

Volumn 12, Issue 7, 2016, Pages C205-C211

  Yu, Qiming ^a   Zhang, Lusha ^b   Fan, Sunfu ^c   Huang, Ling ^a   Wang, Xinbao ^a   Xindun, Cai ^c  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG HOSPITAL   (China)

Author keywords

Chemotherapy; colorectal carcinoma; liver metastases; transarterial chemoembolization

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL RATE; TREATMENT DURATION; AGED; COLORECTAL NEOPLASMS; GENETICS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MORTALITY; MULTIMODAL IMAGING; NEOPLASMS, SECOND PRIMARY; ONCOGENE RAS; PATHOLOGY; PROCEDURES; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; TREATMENT OUTCOME;

EID: 85014372018     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.200603     Document Type: Article

References (27)

1. Gruber-Rouh T, Naguib NN, Eichler K, Ackermann H, Zangos S, Trojan J, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-Term results over a 10-year period. Int J Cancer 2014;134:1225-31.
2. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist 2007;12:825-39.
3. Konopke R, Roth J, Volk A, Pistorius S, Folprecht G, Zöphel K, et al. Colorectal liver metastases: An update on palliative treatment options. J Gastrointestin Liver Dis 2012;21:83-91.
4. Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: Overview. J Hepatobiliary Pancreat Sci 2012;19:523-7.
5. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. J Clin Oncol 2011;29:1083-90.
6. Dudeck O, Ricke J. Advances in regional chemotherapy of the liver. Expert Opin Drug Deliv 2011;8:1057-69.
7. Ghanaati H, Mohammadzadeh V, Mohammadzadeh A, Firouznia K, Mohammadzadeh M, Motevali M, et al. Efficacy of transarterial chemoembolization on lesion reduction in colorectal liver metastases. Acta Med Iran 2012;50:535-40.
8. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-Type unresectable colorectal liver-limited metastases. J Clin Oncol 2013;31:1931-8.
9. Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Results of a phase II clinical study. In Vivo 2007;21:1085-91.
10. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al. DC bead: In vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006;17 (2 Pt 1):335-42.
11. Martin RC, Robbins K, Tomalty D, OHara R, Bosnjakovic P, Padr R, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: An interim report. World J Surg Oncol 2009;7:80.
12. Albert M, Kiefer MV, Sun W, Haller D, Fraker DL, Tuite CM, et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011;117:343-52.
13. You YT, Changchien CR, Huang JS, Ng KK. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. Int J Colorectal Dis 2006;21:33-7.
14. Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: Regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: An update. Eur Radiol 2007;17:1025-34.
15. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, et al. Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 2005;16:425-9.
16. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
17. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 2011;22:1535-46.
18. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14.
19. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 2012;30:1755-62.
20. Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F, et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 2010;10:27.
21. Swan PJ, Welsh FK, Chandrakumaran K, Rees M. Long-Term survival following delayed presentation and resection of colorectal liver metastases. Br J Surg 2011;98:1309-17.
22. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715-22.
23. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: Review and meta-Analysis of prognostic factors. Clin Epidemiol 2012;4:283-301.
24. Jones RP, Jackson R, Dunne DF, Malik HZ, Fenwick SW, Poston GJ, et al. Systematic review and meta-Analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg 2012;99:477-86.
25. Akgöl Ö, Çetinkaya E, Ersöz S, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol 2014;20:6113-22.
26. Zhang D, Yu M, Xu T, Xiong B. Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population. Hepatogastroenterology 2013;60:1297-301.
27. Ribero D, Viganò L, Amisano M, Capussotti L. Prognostic factors after resection of colorectal liver metastases: From morphology to biology. Future Oncol 2013;9:45-57.